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SARS-CoV-2 infection causes an abrupt response by the host immune system, which is
largely responsible for the outcome of COVID-19. We investigated whether the specific
immune responses in the peripheral blood of 276 patients were associated with the sever-
ity and progression of COVID-19.At admission, dramatic lymphopenia of T, B, and NK cells
is associated with severity. Conversely, the proportion of B cells, plasmablasts, circulating
follicular helper T cells (cTfh) and CD56–CD16+ NK-cells increased. Regarding humoral
immunity, levels of IgM, IgA, and IgG were unaffected, but when degrees of severity were
considered, IgGwas lower in severe patients. Compared to healthy donors, complement C3
and C4 protein levels were higher in mild and moderate, but not in severe patients, while
the activation peptide of C5 (C5a) increased from the admission in every patient, regard-
less of their severity. Moreover, total IgG, the IgG1 and IgG3 isotypes, and C4 decreased
from day 0 to day 10 in patients who were hospitalized for more than two weeks, but not
in patients who were discharged earlier. Our study provides important clues to under-
stand the immune response observed in COVID-19 patients, associating severity with an
imbalanced humoral response, and identifying new targets for therapeutic intervention.
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Introduction
Novel coronavirus disease (COVID-19), due to severe acute res-
piratory coronavirus 2 (SARS-CoV-2), is either asymptomatic or
presents with mild symptoms in a majority of individuals. How-
ever, up to 20% of patients develop a severe form of the disease
with pneumonia, which in some cases results in acute respiratory
distress syndrome (ARDS) and requires invasive mechanical ven-
tilation. ARDS, together with myocardial damage, are the main
causes of mortality in COVID-19 [1].
A pathogenic hallmark of ARDS is the disruption of the
alveolar-capillary barrier and a subsequent increase in permeabil-
ity, which has been partially attributed to a maladaptive immune
response. Thus, lung alveolar macrophages may be infected by
the virus and become activated, leading to a cytokine release syn-
drome, which contributes to endothelial injury with the recruit-
ment and activation of innate and adaptive immune cells and
the extravasation of plasma components of the humoral immu-
nity [2].
Humoral immunity plays a key role in the initial control of
viral infections and cell-to-cell spread. It is mediated by the com-
plement system and the immunoglobulins (Ig) [3, 4]. Different
SARS-CoV-2 components such as pathogen-associated molecular
patterns (PAMPs) and N protein, together with C reactive pro-
tein (CRP) from plasma, may activate either the alternative or the
lectin pathways of the complement cascade early during infection
[5]. Furthermore, early IgM isotype antibodies efficiently trigger
the classical complement cascade. Secreted IgA antibodies neu-
tralize viruses within the mucosa of the respiratory and gastroin-
testinal tracts. Finally, in a more advanced stage of the disease,
virus-specific IgG antibodies opsonize viral particles. This may
lead to the formation of immune complexes that contribute to
the activation of the classical complement pathway. Furthermore,
opsonized viral particles can attach to Fc receptors on phago-
cytes and NK cells. The latter constitute major innate immunity
mediators during antiviral responses, since they kill infected cells
through different mechanisms, including antibody-dependent cell
cytotoxicity (ADCC), which is mediated by the FcγRIIIA (CD16)
binding to clustered IgG displayed on the cell surface of virally
infected cells [6]. Isotype switching and affinity antibody matura-
tion, as well as the generation of memory B cells and long-lived
plasma cells, are B cell responses driven by helper T cells, in par-
ticular follicular helper T cells (Tfh).
However, the deregulated humoral immune response can
damage host tissues. Complement-mediated tissue injury is
elicited by an intense inflammatory loop secondary to C3a-
and C5a-mediated recruitment and activation of neutrophils,
monocytes, macrophages, lymphocytes, and platelets. Phagocytes
in turn generate ROS and proteases, and neutrophils release
neutrophil extracellular traps (NETs), which exacerbate tissue
damage [7–10].
Several studies on SARS-CoV-2 infection have attempted to
elucidate phenotypic features of immune cell subsets either asso-
ciated with severity or predictive of disease outcome. However,
these studies have been conducted, in most cases, with a lim-
ited number of patients, and clinical parameters and disease
severity are not homogeneously recorded in all of them [11,12].
Likewise, although specific antibodies and complement activation
have been proposed to mediate some of the most severe com-
plications of coronavirus infections, including that of SARS-CoV-2
[2,5,13,14], solid evidence on the role of humoral immunity effec-
tor mechanisms in the pathogenesis of SARS-CoV-2-associated
ARDS is clearly needed.
Results
COVID-19 patients have increased B cells and
plasmablasts in peripheral blood
Our cohort of COVID-19 patients included 276 SARS-CoV-2
infected individuals who were further classified according to the
severity of their clinical signs and symptoms in mild, moderate,
and severe, following recently described criteria [15]. The mean
duration of symptoms before admission was 7.36 ± 5.2 days.
Table 1 shows the main demographic and laboratory character-
istics. The median (percentile 25 and 75) age was 63 (53.25–75)
and 163 (59.05%) were men.
We conducted an initial analysis following the COVID-19
admission protocol, which comprised the quantification of the
main peripheral blood lymphocyte subsets, including T, B, and
NK lymphocytes as well as plasmablasts, by multiparametric flow
cytometry (Fig. 1A, Suppl. Fig. S1). The proportion of T lympho-
cytes (either CD4+ or CD8+) and NK cells was similar in all the
patients and healthy volunteers, with the exception of CD8+ T
cells, which decreased in severe patients (Fig. 1B). Conversely,
the percentage of B cells was higher in COVID-19 patients and
increased with disease severity, raising from a mean of 9.15%
in healthy donors to 20.49% in severely ill patients. In accor-
dance, plasmablasts were remarkably higher in patients, both in
relative and absolute values (mean 1.51% vs 17.98%; and 2.83
cells/μl vs 27.37 cells/μl, respectively), and regardless of sever-
ity degree (Fig. 1B). This increase in absolute plasmablasts num-
ber is of special relevance, given the lymphopenia present in
COVID-19 patients (Table 1), and the diminished absolute num-
ber of other lymphocyte subsets (Fig. 1B). The elevated num-
ber of plasmablasts suggested a redistribution of the main mat-
uration stages of the B lineage, including naïve, transitional,
unswitched memory, IgM-only memory, and class-switched mem-
ory B-cells, which were identified in a subgroup of 84 patients
from our initial cohort, with the gating strategy shown in Sup-
porting Information Fig. S2. In COVID-19 patients, the propor-
tion of IgM-only memory B-cells increased, while unswitched
memory cells decreased (Fig. 1C). This redistribution was more
marked in mild patients and progressively diminished in moder-
ate and severe patients. Nevertheless, differences among patients
with different severity degree were not statistically significant
(Suppl. Fig. S3).
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Table 1. Demographic and laboratory characteristics of the study population classified by severity degree. All variables are expressed as median
(p25-p75)
Characteristics
(missing data: n, %)
Study population



























































































































































AST, aspartate amino-transferase; ALT, alanine amino-transferase; GGT, gamma-glutamyl transferase; LDH, lactate dehydrogenase; CRP, C-reactive
protein; IL-6, interleukin-6.
Increased follicular helper T cells in the peripheral
blood of COVID-19 patients
Given the role of Tfh in maturation and activation of B cells, we
assessed whether circulating Tfh (cTfh) were increased in the
peripheral blood of COVID-19 patients, in accordance with the
increased number of plasmablasts. We observed that the cTfh pro-
portion significantly increased with the severity of COVID-19 indi-
viduals, shifting from a median of 0.51% in healthy donors to
1.7 % in severely ill patients. Importantly, the absolute number
remained steady despite the profound decrease of total CD4+ T
cells (Fig. 2A, Fig. 1B). To further characterize this population,
we assessed the surface expression of CCR7 chemokine receptor,
which has been related to lower B-cell activation capacity by Tfh
[16, 17]. We found a significant increase in CCR7 expression in
cTfh cells of patients with moderate to severe disease (Fig. 2A).
Finally, we found a direct correlation between cTfh proportion
and total B-cells (r 0.33; p = 0.0090), class-switched B-cells (r =
0.26, p = 0.0433), and plasmablasts (r = 0.33, p = 0.0091) in
peripheral blood (Fig. 2B).
COVID-19 severity associates to serum levels of
immunoglobulins and complement
The high number of plasmablasts prompted us to investigate pos-
sible alterations in Ig concentrations. At the time of admission,
COVID-19 patients had serum concentrations of either IgG, IgA, or
IgM isotypes comparable to those in healthy volunteers (Fig. 3A).
On the other hand, when patients with different degrees of
severity were analyzed, we observed that, in severe cases, the
levels of IgA and IgM were similar, but the IgG concentration was
decreased, compared to healthy volunteers (Fig. 3B). In addition,
a direct correlation was found between IgG (0.37; p = 0.0007)
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Figure 1. Distribution of lymphocyte subpopulations in the peripheral blood of COVID-19 patients characterized bymultiparametric flow cytometry.
(A) Analysis of the distribution of lymphocyte subpopulations by automated clustering and dimensionality reduction FlowSOM tool (Cytobank)
in a representative healthy donor and COVID-19 patient. (B) Boxplots show percentage and absolute number (cells/μl) of distinct lymphocyte
subpopulations in healthy donors (white; n = 19) and COVID-19 patients with different degrees of severity: mild (blue; n = 146), moderate (yellow;
n = 89) and severe (red; n = 41), measured by flow cytometry. (C) Boxplots represent quantification of relevant B cell subpopulations in healthy
donors (n = 19) and selected COVID-19 patients (n = 84) assessed by flow cytometry. Data are from 19 experiments, with a median of 6 patients
analyzed per experiment and day. Boxplots display percentiles 25 and 75 andmedian, and thewhiskers correspond to percentiles 5 and 95.Asterisks
indicate significant differences (p-values for ANOVA Tukey’s contrast test: *p< 0.05, **p<0.01, ***p< 0.001, ****p < 0.0001).
and IgA (0.23; p = 0.0444) serum concentrations and the absolute
number of plasmablasts in peripheral blood, and between IgM lev-
els and total number of peripheral blood IgM- only memory B-cells
(0.36; p = 0.0040) in COVID-19 patients. On the contrary, IgG
(-0.31; p = 0.0147) and IgA (-0.38; p = 0.0021) were inversely
related to the proportion of unswitched memory B cells (Fig. 2B).
The increase in plasma concentrations of IL-6 and acute phase
reactants that characterizes COVID-19 (Table 1) suggested that
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Figure 2. Circulating Tfh lymphocytes are increased in COVID-19 patients. (A) Left: Boxplots showquantification bymultiparametric flow cytometry
of cTfh lymphocytes as percentage or absolute number (cells/μl) in healthy donors (n = 19) and selected COVID-19 patients with different severity
degree (mild (n = 29), moderate (n = 40), and severe (n = 15)). Right: Boxplots show CCR7 MFI of cTfh lymphocytes in healthy donors and COVID-19
patients with different severity degree (mild, moderate, and severe). Boxplots display percentiles 25 and 75 and median, and the whiskers corre-
spond to percentiles 5 and 95. Asterisks indicate significant differences (p-values for ANOVA Tukey’s contrast test: *p<0.05, **p< 0.01, ***p< 0.001,
****p< 0.0001). (B)Annotated heatmap of a correlationmatrix for different variables in those same COVID-19 patients (n= 84).White squares include
non-significant correlations (p > 0.05), red and blue squares include significant indirect and direct correlations (p < 0.05), respectively. Numbers
inside squares and intensity of color correspond to Spearman’s rank correlation coefficient. Variables in the correlation map were reordered using
the hierarchical cluster method. Data are from 19 experiments, with a median of 6 patients per experiment and day. MBC = memory B cells.
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Figure 3. Immunoglobulins and complement levels are altered in COVID-19 patients. (A) Quantification of serum concentration (mg/dl) by neph-
elometry of IgG, IgA, IgM, C3, and C4 in healthy donors (n = 19) and COVID-19 patients (n = 255), and C5a by ELISA in healthy donors (n = 10)
and COVID-19 patients (n = 63). (B) Serum concentration (mg/dL) of IgG, IgA, IgM, C3, and C4 in healthy donors (n = 19) and COVID-19 patients
according to severity degree (mild (n = 138), moderate (n = 82), and severe (n = 35)). Serum concentration (ng/ml) of C5a in healthy donors (n = 10)
and COVID-19 patients according to severity degree (mild (n = 29), moderate (n = 19), and severe (n = 15)). Values represent quantification for each
serum marker depicted as boxplots. Asterisks indicate significant differences (p-values for Mann–Whitney t-test or ANOVA Kruskal–Wallis test, as
appropriate: *p< 0.05, **p< 0.01, ***p< 0.001, ****p < 0.0001). Data are from samples collected over a 6 weeks period and analyzed within 24 h before
freezing the serum. For C5a measurements, samples were thawed and assessed in two independent experiments. Box plots depict percentiles
25 and 75 and the median, and the whiskers show percentiles 5 and 95.
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the concentration of C3 and C4 complement proteins, considered
as acute phase reactants, could also be elevated. Therefore, we
measured C3 and C4 levels in the sera of these patients, and could
detect increased levels of both complement proteins (Fig. 3A).
Accordingly, to investigate whether complement activation occurs
in COVID-19 patients, we quantified C5a, the activation peptide
of complement component C5, which showed increased plasma
levels in most patients (Fig. 3A).
However, when considering different groups of severity, we
observed that C3 and C4 levels increased in patients with mild
to moderate disease, while returned to levels similar to healthy
donors in those with severe disease (Fig. 3B). Therefore, in con-
trast to other inflammatory parameters such as LDH, ferritin
or CRP (Table 1), C3 and C4 values decreased as the severity
increased. Of note, unlike C3 and C4, C5a levels remained ele-
vated in plasma regardless degree of severity (Fig. 3B).
Next, we tested whether the decrease in these components
of humoral immunity was actually related to the severity of the
disease in critical patients, or rather mirrored an increased con-
sumption along time. We then considered a hospitalization period
longer than 15 days as a readout of the severity of the disease
and collected the blood of a subgroup of 37 COVID-19 patients
who were still hospitalized 10 days after admission and com-
pared it to the initial blood test. With this approach, we observed
that antibodies of the IgG, IgA, and IgM isotypes, the IgG sub-
classes IgG1, IgG3, and IgG4 as well as C3, C4, and C5a comple-
ment proteins were similar in all patients at the time of admission
(Figs. 4A and 4B). However, after 10 days, serum concentration
of IgG was significantly lower in patients hospitalized longer than
15 days, whereas levels of IgA and IgM did not change over this
time. Interestingly, whereas IgG1 and IgG3 levels showed a signif-
icant fold decrease in long versus short-stay patients after 10 days
from admission, IgG4 concentration diminished similarly in both
groups of patients. In order to determine whether these changes
corresponded to a specific anti-SARS-CoV-2 response, we quanti-
fied IgG against SARS-CoV-2 RBD and N proteins, which could be
detected at a high titer at day 10 in all cases (Supporting Informa-
tion Fig. S4). On the contrary, anti-CMV IgG levels decreased after
10 days of hospitalization in both groups (Supporting Information
Fig. S4).
Regarding complement, C3 serum levels were stable over time
in both groups of patients. On the other hand, a significant
decrease of C4 concentration was observed after 10 days specifi-
cally in those patients whose severity eventually required a longer
stay (Fig. 4A). These patients however showed sustained C5a lev-
els at this time point (Fig. 4A). Conversely, activation product C5a
decreased in patients who stayed less than 15 days, which did not
show a parallel C4 significant reduction (Fig. 4A).
The decrease in C4 and IgG serum concentrations in severe
COVID-19 cases led us to hypothesize that antigen-antibody com-
plexes were forming in excessive amounts and activating the clas-
sical pathway of the complement system. Therefore, we quantified
immune complexes by enzyme immunoassay in the serum of the
SARS-CoV-2 infected individuals with different levels of severity,
but we did not find detectable levels (data not shown).
Phenotypic features of NK cells from severe COVID-19
patients
The decrease of IgG that characterized severe patients also
suggested a possible role of ADCC, which has been described to
be mediated by specific NK cell subsets [18]. We therefore quan-
tified the main functional subsets of NK cells (CD56brightCD16-,
CD56dimCD16+, CD56-CD16+). A twofold increase in the pro-
portion of CD56-CD16+ NK cells was found in severe COVID-19
patients compared to healthy donors and patients with mild
disease (Fig. 5A). Furthermore, the absolute values of this
population remained similar to those of healthy donors in all
COVID-19 patients, in contrast to the decrease seen for other
lymphocyte populations (Fig. 5A). Further analysis of this pop-
ulation showed significant downregulation of CD16 expression
irrespective of the degree of severity (Fig. 5B). Interestingly,
CD16 level in CD56-CD16+ cells slightly correlated to the serum
concentration of IgG in COVID-19 patients (r = -0.24; p = 0.0496;
Fig. 2B).
Discussion
It has been proposed that the severity of COVID-19 is related to a
dysregulation of the immune response to SARS-CoV-2. However,
there is no precise knowledge of the immune profile of COVID-19
patients with different clinical courses. To address this issue, we
have performed a comprehensive characterization of the immune
cell populations and soluble mediators of the humoral immunity
in the peripheral blood of 276 patients, who presented from mild
to critical illness in a single center during the peak of the pan-
demic in Madrid, Spain.
Plasmablasts were significantly elevated in the peripheral
blood of most COVID-19 patients at the time of admission. In
contrast, Ig levels were similar to those of healthy donors or even
decreased in the case of IgG in critically ill patients. Since patients
were studied at admission, it was feasible that Ig production had
not peaked yet. However, IgG levels further decreased 10 days
after admission in patients with longer hospital stays, which
suggests that IgG decrease was rather related to severe disease
progression. Three possible explanations may account for these
apparently contradictory observations. The first explanation is a
primary antibody immunodeficiency that debuts with COVID-19.
This is supported by the fact that several patients had very low
levels of IgG, IgA, and IgM in serum both at admission and after
10 days. We have not addressed this possibility yet, however, we
plan to carry out studies aimed at verifying this hypothesis by
assessing Ig levels three months after discharge. Second, it is pos-
sible that certain individuals show impaired specific Ig production
(as might appear from the decrease of the titer of CMV-specific
antibodies shown in Supporting Information Fig. S4) after
infection secondary to generalized lymphopenia, altered B cell
maturation, or patient age. Regarding impaired specific Ig pro-
duction, it is known that sepsis triggers immune cell hyperactivity
followed, days later, by immune paralysis, which associates with
© 2021 The Authors. European Journal of Immunology published by
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Figure 4. Humoral response is related to severity in COVID-19 patients. (A) Serum concentration (mg/dl) of IgG, IgA, IgM,C3, C4, and C5a in COVID-19
patients according to their hospitalization period was quantified by nephelometry or ELISA. (B) Fold change of IgG1, IgG3, and IgG4 levels between
day 0 and day +10 after admission. Green boxplots correspond to patients with a hospitalization period of less than 15 days (n = 13) and orange
boxplots to those hospitalizedmore than 15 days (n = 24). C5a quantification in orange boxplots corresponds to n = 15. Asterisks indicate significant
differences (p-values for Mann-Whitney t-test or Wilcoxon t-test, as appropriate: *p<0.05, **p< 0.01, ***p< 0.001, ****p < 0.0001). Data are from
samples collected over a 6 weeks period and analyzed within 24 h before freezing the serum. For IgG1, IgG3, and IgG4 levels measurements,
samples were thawed and assessed within two independent experiments. Boxplots display percentiles 25 and 75 and themedian, and the whiskers
correspond to percentiles 5 and 95.
a poor patient outcome [19]. Different mechanisms may underlie
this process, including dysregulation of T cell subsets [20].
Isotype switching, which results in the production of IgA and IgG
antibodies, is a feature of germinal centers in lymphoid follicles
following the activation and interaction of specific B cells and Tfh
cells. Despite the increase in cTfh cells in COVID-19 patients, cTfh
from individuals with moderate to severe disease express higher
levels of CCR7, which inversely correlates with Tfh capacity for
activating B cells [21] as CCR7 leads to their retention in the T
zone of the lymph node, preventing their interaction with B cells
in the GC [17].
Recent reports have described specific phenotypic features of
cTfh involved in humoral response against SARS-CoV-2 proteins
in convalescent COVID-19 patients [22]. Thus, although cTfh spe-
cific for spike protein were mainly cTfh17 (CXCR3-CCR6+), neu-
tralizing antibody activities were directly related to the presence
of cTfh1 (CXCR3+CCR6-) and cTfh2 (CXCR3-CCR6-) functional
subsets. We have not studied in detail the functional profile of
© 2021 The Authors. European Journal of Immunology published by
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Figure 5. Phenotypic features of NK cells from severe COVID-19 patients. (A) Boxplots show quantification by flow cytometry of the proportion
(left) and absolute values (right) of the three main functional subsets of NK cells in healthy donors (n = 19) and a selected group of COVID-19
patients with different severity degree (mild (n = 29), moderate (n = 40), and severe (n = 15)). (B) Boxplot depict CD16 MFI of CD56dimCD16+ and
CD56–CD16+ NK subpopulations in those same individuals. Asterisks indicate significant differences (p-values for ANOVA Tukey’s contrast test:
*p<0.05, **p<0.01, ***p< 0.001, ****p < 0.0001). Data are from 19 experiments, with a median of six patients per experiment and day. Boxplots depict
percentiles 25 and 75 and the median, and the whiskers correspond to percentiles 5 and 95.
cTfh in our cohort. Hence, further experiments are needed to
establish a possible relationship between the functional pheno-
type of cTfh and severity degree in these patients, and to con-
firm a Tfh–dependent defective B cell activation in COVID-19 that
contributes to a possible immune paralysis at severe stages of the
disease.
Likewise, plasmablasts number in peripheral blood decreases
with age in healthy individuals [23] which could result in reduced
production of specific neutralizing antibodies and contribute to
the severe course in the elderly.
Finally, the decrease in circulating IgG could be secondary
to its deposit in tissues, where they might activate different Fc-
mediated effector mechanisms, including complement-dependent
cytotoxicity. The absence of significant levels of immune com-
plexes in sera of these patients does not rule out their local for-
mation and deposit in the tissues. Interestingly, evidence from
autopsies and/or biopsies of COVID-19 patients suggests that a
widespread complement activation could mediate microvascular
injury and leukocyte infiltration, since deposits of different com-
ponents of the complement system like C5b-9, C4d and MASP
are observed in the microvasculature of the lung [24] or the
skin [5, 13].
Furthermore, the role of complement in the pathogenesis and
severity of other coronavirus infections had already been pro-
posed [12, 25–28]. Thus, Gralinski et al demonstrated with C3-/-,
C4-/-, or Factor B-/- mice that complement activation significantly
contributes to the pathogenesis of SARS caused by SASR-CoV. In
addition, the N protein from either SARS-CoV, MERS, and SARS-
CoV-2 efficiently activates MASP-2, the primary enzymatic initia-
tor of the lectin pathway [5]. Moreover, genomic/proteomic stud-
ies indicate a relevant role of different complement proteins in the
pathogenesis and severity of COVID-19 [29].
The nature of specific antibodies that could activate comple-
ment should, therefore, require further research. For example, a
recent study in a SARS-CoV macaque model that appeared before
the emergence of first cases of COVID-19, demonstrated that a
faster development of neutralizing IgG against SARS-CoV spike
characterized animals who developed severe lung injury [14].
Moreover, S glycoprotein-specific Ab responses were higher and
peaked earlier in deceased patients during the first 15 days after
the appearance of symptoms, but dramatically dropped 5 days
later, coinciding with clinical deterioration [30].
In our cohort, we have found that IgG1 and IgG3 isotypes,
but not IgG4, decreased after 10 days from admission specif-
ically in more severe patients, a finding that could be related
to the greater capacity of those isotypes to mediate the activa-
tion of the classical pathway of complement. Of note, specific
IgG3 antibodies are the first to appear in viral infections [31].
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Likewise, C3 and C4 levels were increased in both mild and mod-
erate patients but not in individuals with severe COVID-19, where
C3 and C4 remained within the normal values or were even lower.
The reasons for these findings include individual variability in C3
and C4 synthesis due to genetic deficiencies or individual genetic
polymorphisms [32–34]. Alternatively, a higher C3 and C4 con-
sumption may occur in severe patients by excessive activation of
either the lectins pathway or the classical pathway through spe-
cific anti-viral antibodies or immune complexes. The selective C4
depletion observed is probably due to the limited amount of C4
in plasma compared to C3, which is one of the most abundant
plasma proteins. In addition, a clear correlation between C3 and
C4 was found in those patients (data not shown), suggesting a
parallel consumption of both proteins which are characteristic of
some autoimmune diseases and severe infections [35–38].
Accordingly, we found increased levels of C5a (the activation
product of C5) also in patients with severe disease. Similarly,
recent reports have demonstrated that C5a and other comple-
ment activation products like C5b-C9 are increased in COVID-19
patients [24, 39]. Hence, sustained high C5a concentration in the
presence of normal or reduced levels of C3 and C4 would support
complement activation in these patients. Quantification of C1q,
mannose-binding lectin, and factor B, among others, could further
clarify which pathways are responsible for complement activation
in COVID-19.
C5a is one of the strongest proinflammatory molecules, since
it has chemoattractant activity and activates most leukocytes. In
particular, C5a promotes the lung sequestration of myeloid cells
[40] and pulmonary dysfunction and exerts procoagulant activ-
ity through several mechanisms, including the induction of tis-
sue factor by endothelial cells and neutrophils, as well as the
upregulation of plasminogen activator inhibitor-1 in mast cells. In
addition, the cytolytically inactive terminal complement complex
C5b-9 induces procoagulant activity through platelet prothrombi-
nase and activates endothelial cells to express adhesion molecules
and tissue factor [41–44]. In summary, our findings support the
idea of complement being involved in the hyperinflammatory syn-
drome and thrombotic microangiopathies observed in COVID-19
patients.
NK cells are involved in the early immune defense against
viral respiratory infections [45]. Actually, several studies from
SARS-CoV and MERS infections, either in patients or animal
models, had already revealed that these cells play an impor-
tant role in fighting coronavirus [46–48]. The behavior of NK
cells in response to SARS-CoV-2 infection is not unique but
similar to that described in other viral infections [49] and in
the previous outbreaks of coronavirus-associated SARS pneumo-
nia. NK cell absolute numbers were reduced in patients com-
pared to non-infected donors, with significantly lower counts in
severe cases than in moderate or mild patients [50–52]. These
authors have found no significant differences either in the pro-
portion of the whole NK population or in their main subsets
CD56bright and CD56dim. However, to our knowledge, the CD56-
CD16+ NK cell subset has not been analyzed yet in the context
of the COVID-19. We have observed that this subpopulation is
clearly expanded in severe patients, and that CD16 expression
is significantly lower in this subset when compared with healthy
donors. This particular CD56-CD16+ population is expanded
in some viral infections and demonstrates cytokine activation
and ADCC activity in some settings. However, CD56-CD16+ NK
cells have been shown to have less functionality and lower expres-
sion of natural cytotoxicity receptors in other situations [18, 53,
54]. Compared to peripheral blood, the normal human lung is
enriched in NK cells, which present a differentiated phenotype
and have the capacity to respond to viral infections [55, 56]. But
the persistence of highly active NK cells in the lung may exacer-
bate inflammation and result in intense and irreversible damage
of the airway epithelial cells [57, 58].
Many questions arise from the experimental data provided
in this work. Whether the normal levels of C3 and C4 of our
severe patients are reflecting a primary or secondary complement
immunodeficiency or, on the contrary, excessive activation of com-
plement, is not known. Is the NK CD56-CD16+ subset promot-
ing host defense or mediating tissue injury? Are they contribut-
ing to the antiviral response or reflecting a severely compromised
innate immune response? At any rate, the increase of cTfh cells
and the NK CD56-CD16+ subset, the low levels of total IgG, or
the decrease of IgG1 and IgG3 over time that characterize severe
patients open new exploratory avenues of research.
Thus, while the immune system is required for protection from
SARS-CoV-2 infection, its response, if excessive or sustained over
time, like that occurring in COVID-19, may perpetuate both ongo-
ing inflammation and the hypercoagulable state. It is, therefore,
necessary to provide more insights related to individual charac-
teristics and the particular kinetics of the host response to SARS-
CoV-2, to further understand the pathogenesis of COVID-19 and
to decide the appropriate therapy and the treatment timing. This
knowledge is of particular therapeutic relevance since it is the
basis for clinical trials with the different immune modulators that
are currently available including intravenous immunoglobulins,
hyperimmune plasma, or complement inhibitors, among others
[59–61].
Material and methods
Study design and population
This is a retrospective observational study including 276 consec-
utive patients with confirmed detection of SARS-CoV-2 RNA, and
admitted to the Accident and Emergency Department of the Hos-
pital Universitario La Princesa because of mild to critical COVID-
19 symptoms, from February 27 to April 29, 2020.
Data collection
Demographic and laboratory data described in Table 1 were
collected from electronic clinical records and included in an
anonymized database. Baseline evaluation of immunity was
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performed around the 3rd day of admission (median = 3 days;
percentile 25–75 [p25-p75] 2 to 6). A second evaluation was
obtained around the 14th day of admission (median = 14 days;
p25-p75 12 to 16.5) in a selected group of 37 patients.
SARS-CoV-2 RNA detection
Samples from nasopharyngeal and throat exudates were obtained
with specific swabs as previously described [62]. As first-line
screening, we performed real-time RT-PCR assay targeting the E
gene of SARS-CoV-2, with Real-Time ready RNA Virus Master on
Applied Biosystems TM Quant Studio-5 Real-Time PCR System.
This assay was followed by confirmatory testing with the assay
TaqPathTM COVID-19 CE-IVD Kit RT-PCR Applied BiosystemsTM
(ThermoFisher Scientific, Waltham, MA USA), which contains a
set of TaqMan RT PCR assays for in vitro diagnostic use. This
kit includes three assays that target SARS-CoV-2 genes (Orf1ab,
S gene, N gene) and one positive control assay that targets the
human RNase P RPPH1 gene [63]. Determinations were carried
out in an Applied BiosystemsTM QuantStudio-5 Real-Time PCR
System (CA, USA).
Sample collection and flow cytometry analysis
Peripheral blood samples from 276 COVID-19 patients were
obtained in EDTA tubes for flow cytometry assessment around the
3rd day of admission. The distribution of the different leukocyte
subsets was characterized by multiparametric flow cytometry
within 24 h after extraction following the Guidelines for the
use of flow cytometry and cell sorting in immunological studies
[64]. To this end, 200 μL of whole fresh blood were stained
in a BD OneFlowTM LST from BD Biosciences (San José, CA,
USA) designed to identify and quantify the main lymphocyte
populations of T (CD3+, CD4+, CD8+, γδ+), B, and NK lineages.
Absolute cell numbers were calculated from white blood cell
counts obtained with an XN-10 Hematology System (Sysmex,
Kobe, Japan- Roche, Basel, Switzerland).
A subgroup of 84 patients were randomly selected during the
period of study for extensive characterization of their lymphocyte
subsets. These patients, as well as 19 healthy donors, were stud-
ied with an extended panel of multicolor monoclonal antibodies
(mAbs): anti-CD4 FITC, anti-IgD FITC, anti-PD-1 PE, anti-CD56
PE, anti-CD27 PE, anti-CD38 PerCP/Cy5.5, anti-CXCR5 AF647,
anti-IgM APC, anti-CD19 PE-Cy7, anti-CD8 APC/H7, anti-CD10
APC/H7, anti-CCR7 BV421, anti-CD16 V450, anti-CD3 V500 from
BD Biosciences (USA); and anti-CD20 V450 from Immunostep
(Spain).
Samples were incubated for 30 min at room temperature with
the respective mAbs. Then, erythrocytes were lysed with FACS
lysis solution (BD Biosciences) for 10 minutes and after wash-
ing with PBS, samples were analyzed in a FACS Canto II device
(BD). At least 100 cells of the less represented subsets were col-
lected and data were analyzed with the FACSDiva and FlowJo
Softwares from BD Biosciences. The different leukocyte subsets
were assigned according to the strategy showed in supplementary
Fig. S1.
Data are expressed as a percentage or absolute number in
cells/μl of a given lymphocyte subpopulation. A dual-platform
method was used to calculate absolute cell counts. Mean fluo-
rescence intensity (MFI) was employed to compare the level of
expression of certain molecules.
Serum concentrations of immunoglobulins and
complement proteins
Serum samples were tested by immunonephelometry for total
IgG, IgA, IgM, C3, and C4 concentrations (Immage800, Beckman
Coulter, California, USA) and for IgG1, IgG3 and IgG4 (Optilite,
The Binding Site, Birmingham, UK). C5a quantification was per-
formed with the MicroVue C5a ELISA kit (Quidel, Athens, USA)
following manufacturer´s instructions. In addition, 19 serum sam-
ples from healthy donors obtained during the same period time
were used to determine the variability of Ig, C3 and C4 and C5a
levels in normal conditions. The absence of SARS-CoV-2 infection
in healthy donors at the time of extraction was confirmed by ret-
rospective determination of specific antibodies. The presence of
circulating immunocomplexes was assessed with C1q CIC ELISA
Kit (INOVA, San Diego, USA) following manufacturer´s instruc-
tions.
Detection of specific antibodies against SARS-CoV-2
and Cytomegalovirus
Nucleoprotein (NP) and the Receptor Binding Domain (RBD)
of SARS-CoV-2 were produced and ELISA was performed as
described by Martinez-Fleta et al.[65]. 96-Well Maxisorp Nunc-
Immuno plate was coated with 100 μl/well of recombinant pro-
teins diluted in 0.1 M borate buffered saline (BBS) pH 8.8; NP at
0.5 μg/ml, RBD at 1μg/ml and incubated overnight at 4°C. Coat-
ing solutions were then aspirated, the ELISA plates were washed
three times with 200 μl of PBS 0.05% Tween 20 (PBS-T) and
blocked with 200 μl PBS-casein (Biorad, 1× PBS blocker) for 1 h
at room temperature. The plates were washed again with PBS-T
and 100 μl of patient serum sample diluted in PBS-casein, 0.02%
Tween-20, was added and incubated for 2 h at room tempera-
ture. The plates were washed again and 100 μl/well of AffiniPure
Rabbit Anti-Human IgG (Fcγ fragment specific) from Jackson
Labs was added and incubated for 1 hour at room temperature.
The plates were washed with PBS-T four times and incubated
at room temperature in the dark with 100 μL/well of Substrate
Solution (OPD, Sigma prepared according to the manusfacturer’s
instructions) (typically for 3 minutes). 50 μL of stop solution (3M
H2SO4) were then added to each well and the OD (at 492nm) of
each well was determined using a microplate reader.
Negative controls included wells coated just with blocking
buffer and serum samples collected from healthy donors before
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2019. The cut-off was established by comparison with the result
of a positive serum sample.
Serum samples were also assessed with an anti-CMV/IgG
detection kit (Enzygnos, Siemens), following manufacturer’s
instructions.
Statistics
Descriptive results were expressed as mean ± SD or median and
percentile 25-percentile 75 (p25-p75), as appropriate, while qual-
itative variables are presented as frequency (n) and relative per-
centages of patients (%). The unpaired, two-tailed, Student t-test
was used to compare two independent groups and the paired Stu-
dent t-test, to analyze two related samples. One-way ANOVA was
employed to compare more than two groups and post hoc mul-
tiple comparisons were made with Tukey’s test. Spearman bivari-
ate correlations were performed between serological quantitative
markers and cell populations and corrplot R package (available
from: https://github.com/taiyun/corrplot) was used for correla-
tion map graphics. Variables in correlation map were reordered
using the hierarchical cluster method. The p-values were two-
sided and statistical significance was considered when p < 0.05.
To analyze the distribution of lymphocytes in COVID-19 patients
and healthy donors, an automated clustering and dimensional-
ity reduction were performed using viSNE and FlowSOM tools
(Cytobank). Population cells were normalized using log trans-
formation for analysis. Differences in normalized cells between
healthy donors and severity groups (adjusted by sex and age)
were assessed with a moderated t-test using limma R package
[66]. Cell populations that showed significant P-value (FDR =
5%) were considered as differentially expressed between groups.
Stata v. 12.0 for Windows and R version 3.5.1 was used for anal-
yses and graphics. GraphPad Prism 4 software was also used for
graphics. Data are presented making specification for p < 0.05
(*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****).
Study approval
This study was approved by the local Research Ethics Commit-
tee (register number 4070) and it was carried out following the
ethical principles established in the Declaration of Helsinki. All
included patients were informed about the study and gave an
oral informed consent because of COVID-19 emergency as pro-
posed by AEMPS (Agencia Española del Medicamento y Productos
Sanitarios).
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